Analysts think NBIX stock price could increase by 49%
May 05, 2025, 11:25 AM
13.92%
What does NBIX do
Neurocrine Biosciences, based in San Diego, develops pharmaceuticals for neurological disorders and employs 1,448 people. Its FDA-approved products include INGREZZA and Orilissa, with a strong clinical development pipeline.
27 analysts think NBIX stock price will increase by 48.70%. The current median analyst target is $163.20 compared to a current stock price of $109.75. The lowest analysts target is $96.96 and the highest analyst target is $201.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
